Lilly Eyes Aesthetic Medicine as GLP-1 Weight Loss Reshapes Faces
Eli Lilly is exploring aesthetic medicine as GLP-1 patients face facial volume loss and laxity — but no products, trials, or timelines are confirmed yet.
Section
Company news, product launches and regulatory action in skin care.
Eli Lilly is exploring aesthetic medicine as GLP-1 patients face facial volume loss and laxity — but no products, trials, or timelines are confirmed yet.
Galderma will buy ZO Skin Health from Blackstone and the Obagi family for $1.5 billion, adding the physician-dispelled skincare b…
The CHMP has issued a positive opinion backing six-weekly cemiplimab dosing across all EU indications, potentially halving annual…
Sanofi and pCPA have signed a Letter of Intent covering Dupixent across four dermatology and respiratory indications. The bundled…
Sanofi and the pCPA have signed a letter of intent on Dupixent pricing across four dermatology and respiratory indications, openi…
Galderma is acquiring ZO Skin Health for $1.5 billion, per NewBeauty, in one of the year's largest dermatology-channel deals and…
SciBase has secured its first US payer coverage from a major insurer for its non-invasive skin assessment platform, a step the co…
Galderma will pay US$1.5 billion to acquire ZO Skin Health, framing the deal as an expansion of its dermatological skin-care port…
Sparse details have emerged since the FDA cleared a new sunscreen active, 1310 WIBA reported. Clinicians await the molecule, conc…
The FDA has approved a new sunscreen ingredient and products containing it are already on U.S. retail shelves, per a WSPD report…